Results 81 to 90 of about 15,419 (219)

Epidemiological Insights Into Polycystic Liver Disease: Data From Forensic Autopsies in Portugal

Liver International Communications, Volume 7, Issue 1, March 2026.
ABSTRACT Polycystic liver disease (PLD) is a rare hereditary disorder characterised by multiple hepatic cysts, occurring either in isolation or in association with autosomal dominant polycystic kidney disease (ADPKD). Population‐based prevalence data are scarce, and no national data are available for Portugal.
Laura Martins, Agostinho Santos, João Paulo Oliveira   +2 more
wiley   +1 more source

Characterizing the ADPKD-IFT140 Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers

Kidney International Reports
Introduction: ADPKD-IFT140 is the third most common disease-causing variant in autosomal dominant polycystic kidney disease (ADPKD) after ADPKD-PKD1 and ADPKD-PKD2.
Ahmad Ghanem, Fadi George Munairdjy Debeh, Abdul Hamid Borghol, Nikola Zagorec, Amanda L. Tapia, Byron Smith, Stefan Paul, Abdul Basit, Bassel AlKhatib, Nay Nader, Marie Therese Bou Antoun, Adriana V. Gregory, Hana Yang, Rachel S. Schauer, Neera K. Dahl, Christian Hanna, Vicente E. Torres, Timothy L. Kline, Peter C. Harris, Emilie Cornec-Le Gall, Fouad T. Chebib   +20 more
doaj   +1 more source

Multicystic Kidney Disease in a Family With Tuberous Sclerosis Complex

Nephrology, Volume 31, Issue 3, March 2026.
ABSTRACT Tuberous sclerosis complex (TSC) is a multisystem condition associated with disease‐causing variants of either TSC1 or TSC2 genes. Significant kidney involvement in TSC is most often due to development of angiomyolipomas (AMLs) and occurs more frequently in people with TSC2 variants.
Julia S. Donald, Caitlin Edmonstone, Denise L. Chan, Clara W. T. Chung, Sean E. Kennedy   +4 more
wiley   +1 more source

Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK‐52E rat kidney epithelial cells

Physiological Reports, Volume 14, Issue 6, March 2026.
CRISPR–Cas9–mediated PKD1 knockout in NRK‐52E rat kidney epithelial cells induces glycolytic reprogramming. Hyperpolarized [1‐13C]pyruvate magnetic resonance spectroscopy reveals increased pyruvate‐to‐lactate conversion accompanied by elevated lactate dehydrogenase activity and altered monocarboxylate transporter expression.
Ida Kjær Mieritz, Christoffer Laustsen, Esben Axelgaard, Sofie Rahbek Dorset, Rasmus O. Bak, Lotte Bonde Bertelsen   +5 more
wiley   +1 more source

Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. [PDF]

PLoS ONE, 2014
Autosomal dominant polycystic kidney disease (ADPKD) is clinically heterogenic. Biomarkers are needed to predict prognosis and guide management. We aimed to profile microRNA (miRNA) in ADPKD to gain molecular insight and evaluate biomarker potential ...
Iddo Z Ben-Dov, Ying-Cai Tan, Pavel Morozov, Patricia D Wilson, Hanna Rennert, Jon D Blumenfeld, Thomas Tuschl   +6 more
doaj   +1 more source

Renal effects of short‐term ketone monoester supplementation in healthy adults: A randomized, placebo‐controlled study

Physiological Reports, Volume 14, Issue 6, March 2026.
Randomized, double‐blind, placebo‐controlled crossover study examining the renal effects of five days of ketone monoester supplementation in healthy participants. Exogenous ketosis increased glomerular filtration rate (GFR) and fractional sodium excretion (FENa) during the examination day.
Trine Z. Lyksholm, Camilla L. Duus, Steffen F. Nielsen, Henrik H. Thomsen, Jesper N. Bech   +4 more
wiley   +1 more source

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Drugs in Context, 2015
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure.
Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin   +7 more
doaj   +1 more source

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

BMC Nephrology, 2019
BackgroundThe short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to predict
H. Bennett, P. McEwan, Karin Hamilton, K. O’Reilly   +3 more
semanticscholar   +1 more source

Mettl3‐Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS

Advanced Science, Volume 13, Issue 10, 18 February 2026.
This study explores the roles of Mettl3‐induced N6‐methyladenosine (m6A) modifications in Focal segmental glomerulosclerosis (FSGS). The findings reveal that inhibition of Mettl3 results in podocyte injury by modulating the TJP1CDC42 pathway. Moreover, Administration of N6‐methyladenosine attenuates the FSGS phenotype in WT mice induced by Adriamycin ...
Fubin Zhu, Hongzhi Li, Xiang Li, Chunxiu Du, Ting Wang, Xuling Zhou, Xiaobei Xie, Yunxia Shao, Yingzhi Huang, Yanling Hu, Xinxin Guo, Bin Zhu, Shanshan Yu, Xiaoyan Zhang, Binghai Zhao   +14 more
wiley   +1 more source

Association of autosomal dominant polycystic kidney disease (ADPKD) with cardiovascular disease and mortality in patients with treated kidney failure

BMC Nephrology
Introduction Autosomal dominant polycystic kidney disease (ADPKD) is a multisystem syndrome associated with significant morbidity and mortality, particularly kidney failure.
Julia Jefferis, Andrew J. Mallett, Gopi Rangan, Yeoungjee Cho, Andrea K. Viecelli, Venkat Vangaveti, David W. Johnson, Carmel M. Hawley   +7 more
doaj   +1 more source